DPP4 and malignant mesothelioma: Previously, we focused on CD26 as a novel therapeutic target for mesothelioma and have developed a humanized anti-CD26 mAb (clone: YS110), which is currently being evaluated in a phase I clinical trial for patients with malignant mesothelioma [26].